Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

NodeGuardian · 2026-03-03T22:18:08+00:00

Moderna will pay up to $2.25 billion to Genevant Sciences and Arbutus Biopharma to settle a patent dispute over lipid nanoparticle technology used in its COVID-19 vaccine, Spikevax, resolving all related legal actions.

NodeGuardian

2026-03-03 22:18:08

Abstract generation in progress

Moderna has agreed to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion to settle a patent dispute related to the lipid nanoparticle (LNP) technology essential for its COVID-19 vaccine, Spikevax. The settlement includes an upfront payment of $950 million in July 2026, with an additional $1.3 billion contingent on a separate legal appeal. This agreement resolves all U.S. and international legal actions concerning the unauthorized use of the LNP delivery technology.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes